Association between Serum Cystatin C and Vascular Complications in Type 2 Diabetes Mellitus without Nephropathy

被引:18
|
作者
Kim, Hye Jeong [1 ]
Byun, Dong Won [1 ]
Suh, Kyoil [1 ]
Yoo, Myung Hi [1 ]
Park, Hyeong Kyu [1 ]
机构
[1] Soonchunhyang Univ, Coll Med, Soonchunhyang Univ Hosp, Div Endocrinol & Metab,Dept Internal Med, 59 Daesagwan Ro, Seoul 04401, South Korea
关键词
Cystatin C; Diabetes complications; Diabetes mellitus; CORONARY-HEART-DISEASE; CARDIOVASCULAR EVENTS; RETINOPATHY;
D O I
10.4093/dmj.2018.0006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recent studies have correlated serum cystatin C (CysC) with vascular complications, but few studies have investigated this correlation in diabetes patients without nephropathy. This study aimed to evaluate if higher serum CysC levels increase the risk for vascular complications in type 2 diabetes mellitus patients with normal renal function or mild renal impairment. Methods: A total of 806 consecutive patients with type 2 diabetes mellitus who were admitted to the diabetes center of Soonchunhyang University Hospital for blood glucose control were retrospectively reviewed. Patients with nephropathy were excluded. Subjects were categorized into quartiles of serum CysC levels (Q1, <= 0.65 mg/L; Q2, 0.66 to 0.79 mg/L; Q3, 0.80 to 0.94 mg/L; and Q4, >= 0.95 mg/L). Results: The proportion of patients with diabetic retinopathy (DR) (P for trend < 0.001), coronary heart disease (CHD) (P for trend < 0.001), and stroke (P for trend < 0.001) increased across the serum CysC quartiles. After adjustment for confounding factors, the highest serum CysC level remained a significant risk factor for DR (odds ratio [OR], 1.929; 95% confidence interval [CI], 1.007 to 4.144; P=0.040). Compared with Q1, a significant positive association was observed between serum CysC and CHD in Q2 (OR, 7.321; 95% CI, 1.114 to 48.114; P=0.012), Q3 (OR, 6.027; 95% CI, 0.952 to 38.161; P=0.020), and Q4 (OR, 8.122; 95% CI, 1.258 to 52.453; P=0.007). No associations were observed between CysC and stroke after additional adjustment for confounding variables. Conclusion: Serum CysC levels are independently associated with DR and CHD, suggesting that CysC may be useful for identifying type 2 diabetes mellitus patients without nephropathy who are at high risk for vascular complications.
引用
收藏
页码:513 / 518
页数:6
相关论文
共 50 条
  • [1] Association between serum cystatin C and vascular complications in type 2 diabetes without nephropathy
    Park, H.
    Lee, J.
    Kim, H.
    Byun, D.
    Suh, K.
    Yoo, M.
    [J]. DIABETOLOGIA, 2018, 61 : S579 - S579
  • [2] Diagnostic Accuracy of Serum Cystatin C for Early Recognition of Nephropathy in Type 2 Diabetes Mellitus
    Sapkota, Suman
    Khatiwada, Saroj
    Shrestha, Shrijana
    Baral, Nirmal
    Maskey, Robin
    Majhi, Shankar
    Chandra, Lal
    Lamsal, Madhab
    [J]. INTERNATIONAL JOURNAL OF NEPHROLOGY, 2021, 2021
  • [3] Serum cystatin C as an indicator for early detection of diabetic nephropathy in type 2 diabetes mellitus
    Elsayed, Mohamed Shawky
    El Badawy, Ayman
    Ahmed, Abdelmon'em
    Omar, Rasha
    Mohamed, Amr
    [J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2019, 13 (01) : 374 - 381
  • [4] Evaluation of serum cystatin C and chromogranin A as markers of nephropathy in patients with Type 2 diabetes mellitus
    Mojiminiyi, OA
    Abdella, N
    George, S
    [J]. SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2000, 60 (06): : 483 - 489
  • [5] Serum cystatin C and the incidence of type 2 diabetes mellitus
    Sahakyan, K.
    Lee, K. E.
    Shankar, A.
    Klein, R.
    [J]. DIABETOLOGIA, 2011, 54 (06) : 1335 - 1340
  • [6] Serum cystatin C and the incidence of type 2 diabetes mellitus
    K. Sahakyan
    K. E. Lee
    A. Shankar
    R. Klein
    [J]. Diabetologia, 2011, 54 : 1335 - 1340
  • [7] Dyslipidemia and serum cystatin C levels as biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus
    Dejenie, Tadesse Asmamaw
    Abebe, Endeshaw Chekol
    Mengstie, Misganaw Asmamaw
    Seid, Mohammed Abdu
    Gebeyehu, Natnael Atnafu
    Adella, Getachew Asmare
    Kassie, Gizchew Ambaw
    Gebrekidan, Amanuel Yosef
    Gesese, Molalegn Mesele
    Tegegne, Kirubel Dagnaw
    Anley, Denekew Tenaw
    Feleke, Sefineh Fenta
    Zemene, Melkamu Aderajew
    Dessie, Anteneh Mengist
    Moges, Natnael
    Kebede, Yenealem Solomon
    Bantie, Berihun
    Adugna, Dagnew Getnet
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [8] APLICATION OF SERUM CYSTATIN C FOR PREDICTION OF NEPHROPATHY AND CARDIOVASCULAR DISEASES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Pasko, Nevi
    Strakosha, Ariana
    Toti, Florian
    Cadri, Vilma
    Mumajesi, Suela
    Dedej, Teuta
    Stefa, Enkeleda
    Barbullushi, Myftar
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 614 - 614
  • [9] The relationship between serum cystatin C and atherosclerosis in patients with type 2 diabetes mellitus
    Sohn, Tae Seo
    Lee, Jee In
    Lee, Seung Su
    Lee, Jung Min
    Chang, Sang Ah
    Moon, Sung Dae
    Han, Je Ho
    Yoo, Soon Jib
    Son, Hyun Shik
    Cha, Bong Yun
    [J]. DIABETES, 2008, 57 : A626 - A627
  • [10] Association between Cardiovascular Autonomic Neuropathy and Cystatin C in Type 2 Diabetes Mellitus
    Lee, Hong Seok
    Ban, Woo Ho
    Kim, Yeon Ji
    Kim, Bo Kyung
    Ha, Won Chul
    Oh, Su Jin
    Son, Hyun Shik
    Sohn, Tae Seo
    [J]. DIABETES, 2013, 62 : A153 - A153